scispace - formally typeset
D

David M. Schmierer

Researcher at University of Otago

Publications -  10
Citations -  246

David M. Schmierer is an academic researcher from University of Otago. The author has contributed to research in topics: Aminorex & Dopaminergic. The author has an hindex of 9, co-authored 10 publications receiving 235 citations.

Papers
More filters
Journal ArticleDOI

Veratrum Poisoning

TL;DR: Several species of the Veratrum genus are associated with toxicity in humans and animals as mentioned in this paper and the principal toxins are steroid alkaloids; some have a modified steroid template, whereas others differ in their esterified acid moieties.
Journal ArticleDOI

Application of an online post-column derivatization HPLC-DPPH assay to detect compounds responsible for antioxidant activity in Sonchus oleraceus L. leaf extracts.

TL;DR: An online assay is used to identify key antioxidants in Sonchus oleraceus leaf extracts and to investigate the effect of leaf position and extraction conditions on antioxidant concentration and activity.
Journal ArticleDOI

The effects of an orally administered probiotic on sulfasalazine metabolism in individuals with rheumatoid arthritis: a preliminary study.

TL;DR: Patients with rheumatoid arthritis stabilized on SSZ are enrolled for a pilot study to investigate the effect of short‐term oral probiotic administration on the metabolism of sulfasalazine.
Journal ArticleDOI

Cytokinins and fruit development in the kiwifruit (Actinidia deliciosa). I. Changes during fruit development

TL;DR: The accumulation of cytokinin (mostly zeatin riboside orZeatin nucleotide) in mature fruit may be of significance for the postharvest storage of kiwifruit fruit.
Journal ArticleDOI

Simultaneous qualitative and quantitative analysis of counterfeit and unregistered medicines using Raman spectroscopy

TL;DR: The potential for Raman spectroscopy combined with multivariate analysis for qualitative and semiquantitative analysis of counterfeit medicines was demonstrated, and the approach may be used to determine the potential level of harm in counterfeit medicines on the basis of API identity and amount.